SE464059C - Användning av inositoltrifosfat för framställning av läkemedel - Google Patents

Användning av inositoltrifosfat för framställning av läkemedel

Info

Publication number: SE464059C
Authority: SE; Sweden
Prior art keywords: inositol; phosphate; hydrogen; triphosphate; hydroxyl
Prior art date: 1988-09-15

Application number

SE8803248A

Other languages

English (en)

Swedish (sv)

Other versions

SE464059B (sv

SE8803248L (sv

SE8803248D0 (sv

Inventor

Matti Siren

Original Assignee

Perstorp Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-15

Filing date

1988-09-15

Publication date

1997-06-02

1988-09-15 Application filed by Perstorp Ab filed Critical Perstorp Ab

1988-09-15 Priority to SE8803248A priority Critical patent/SE464059C/sv

1988-09-15 Publication of SE8803248D0 publication Critical patent/SE8803248D0/xx

1989-09-14 Priority to JP1237428A priority patent/JPH02191218A/ja

1989-09-14 Priority to DE68922165T priority patent/DE68922165T2/de

1989-09-14 Priority to AT89117029T priority patent/ATE120958T1/de

1989-09-14 Priority to EP89117029A priority patent/EP0359257B1/de

1989-09-14 Priority to ES89117032T priority patent/ES2054965T3/es

1989-09-14 Priority to GB8920811A priority patent/GB2223404B/en

1989-09-14 Priority to EP89117028A priority patent/EP0359256B1/de

1989-09-14 Priority to GB8920804A priority patent/GB2223167B/en

1989-09-14 Priority to DE89117032T priority patent/DE68906106T2/de

1989-09-14 Priority to ES89117029T priority patent/ES2073419T3/es

1989-09-14 Priority to JP1237427A priority patent/JP2547257B2/ja

1989-09-14 Priority to JP1237431A priority patent/JP3058334B2/ja

1989-09-14 Priority to DE8989117028T priority patent/DE68904507T2/de

1989-09-14 Priority to EP89117030A priority patent/EP0359258B1/de

1989-09-14 Priority to EP89117032A priority patent/EP0359260B1/de

1989-09-14 Priority to ES89117031T priority patent/ES2043998T3/es

1989-09-14 Priority to AT8989117030T priority patent/ATE104855T1/de

1989-09-14 Priority to AT89117032T priority patent/ATE88347T1/de

1989-09-14 Priority to AT89117031T priority patent/ATE79542T1/de

1989-09-14 Priority to GB8920806A priority patent/GB2223169B/en

1989-09-14 Priority to DE8989117031T priority patent/DE68902526T2/de

1989-09-14 Priority to GB8920807A priority patent/GB2223403B/en

1989-09-14 Priority to GB8920805A priority patent/GB2223168B/en

1989-09-14 Priority to ES89117028T priority patent/ES2045319T3/es

1989-09-14 Priority to JP1237430A priority patent/JP2859319B2/ja

1989-09-14 Priority to EP89117031A priority patent/EP0359259B1/de

1989-09-14 Priority to DE68914922T priority patent/DE68914922T2/de

1989-09-14 Priority to AT89117028T priority patent/ATE84719T1/de

1989-09-14 Priority to JP1237429A priority patent/JP2859318B2/ja

1989-09-14 Priority to ES89117030T priority patent/ES2055772T3/es

1990-03-16 Publication of SE8803248L publication Critical patent/SE8803248L/

1990-10-24 Priority to SE9003395A priority patent/SE9003395L/

1991-03-04 Publication of SE464059B publication Critical patent/SE464059B/sv

1992-08-20 Priority to GR920400982T priority patent/GR3005448T3/el

1993-01-21 Priority to GR920402459T priority patent/GR3006825T3/el

1993-04-22 Priority to GR930400188T priority patent/GR3007686T3/el

1995-04-13 Priority to GR940403975T priority patent/GR3015764T3/el

1997-06-02 Publication of SE464059C publication Critical patent/SE464059C/sv

Links

239000003814 drug Substances 0.000 title claims abstract description 27
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 title claims description 22
229940079593 drug Drugs 0.000 title description 14
238000002360 preparation method Methods 0.000 title description 5
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 20
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 11
229960000367 inositol Drugs 0.000 claims description 11
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 10
GKDKOMAJZATYAY-GCVPSNMTSA-N [(1r,2s,4r,5r)-2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1O GKDKOMAJZATYAY-GCVPSNMTSA-N 0.000 claims description 8
150000003839 salts Chemical group 0.000 claims description 8
230000000740 bleeding effect Effects 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 5
229910052791 calcium Inorganic materials 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000001226 triphosphate Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
239000011701 zinc Substances 0.000 claims description 3
229910052725 zinc Inorganic materials 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 abstract description 32
MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 abstract 2
102000004895 Lipoproteins Human genes 0.000 abstract 1
108090001030 Lipoproteins Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 description 50
235000021317 phosphate Nutrition 0.000 description 50
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 47
239000010452 phosphate Substances 0.000 description 47
229910052739 hydrogen Inorganic materials 0.000 description 45
239000001257 hydrogen Substances 0.000 description 45
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 44
125000002887 hydroxy group Chemical group [H]O* 0.000 description 31
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 11
229910052698 phosphorus Inorganic materials 0.000 description 11
239000011574 phosphorus Substances 0.000 description 11
-1 R 1 Chemical compound 0.000 description 10
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 10
230000007062 hydrolysis Effects 0.000 description 9
238000006460 hydrolysis reaction Methods 0.000 description 9
239000007858 starting material Substances 0.000 description 8
239000000126 substance Substances 0.000 description 7
108010011619 6-Phytase Proteins 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 description 5
238000005342 ion exchange Methods 0.000 description 5
229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
230000037396 body weight Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
229930014626 natural product Natural products 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
229960001948 caffeine Drugs 0.000 description 3
159000000007 calcium salts Chemical class 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
239000012528 membrane Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229940085127 phytase Drugs 0.000 description 3
229940068041 phytic acid Drugs 0.000 description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
239000000047 product Substances 0.000 description 3
239000007974 sodium acetate buffer Substances 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003729 cation exchange resin Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011707 mineral Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229920000137 polyphosphoric acid Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
229910052711 selenium Inorganic materials 0.000 description 2
239000011669 selenium Substances 0.000 description 2
229940083982 sodium phytate Drugs 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000013566 allergen Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002050 anti-rickettsial effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
CDAISMWEOUEBRE-JMVOWJSSSA-N cis-inositol Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-JMVOWJSSSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000005336 cracking Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
235000020664 gamma-linolenic acid Nutrition 0.000 description 1
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
229960002733 gamolenic acid Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
CDAISMWEOUEBRE-GNIYUCBRSA-N muco-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-GNIYUCBRSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)
External Artificial Organs (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SE8803248A 1988-09-15 1988-09-15 Användning av inositoltrifosfat för framställning av läkemedel SE464059C (sv)

Priority Applications (36)

Application Number	Priority Date	Filing Date	Title
SE8803248A SE464059C (sv)	1988-09-15	1988-09-15	Användning av inositoltrifosfat för framställning av läkemedel
ES89117030T ES2055772T3 (es)	1988-09-15	1989-09-14	Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.
AT89117032T ATE88347T1 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat zur herstellung eines arzneimittels gegen abnorme konzentrationen von lipoproteinen.
AT89117031T ATE79542T1 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat zur herstellung eines arzneimittels gegen stoerungen bei transplantationen.
AT89117029T ATE120958T1 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat zur herstellung eines arzneimittels gegen diabetes.
EP89117029A EP0359257B1 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen Diabetes
ES89117032T ES2054965T3 (es)	1988-09-15	1989-09-14	El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.
GB8920811A GB2223404B (en)	1988-09-15	1989-09-14	Inositoltrisphosphate for the treatment of abnormal levels of lipoproteins
EP89117028A EP0359256B1 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat bei der Behandlung der Beschädigung von Gewebe
GB8920804A GB2223167B (en)	1988-09-15	1989-09-14	Inositoltrisphosphate for the treatment of tissue damage
DE89117032T DE68906106T2 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen abnorme Konzentrationen von Lipoproteinen.
DE8989117031T DE68902526T2 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat zur herstellung eines arzneimittels gegen stoerungen bei transplantationen.
JP1237427A JP2547257B2 (ja)	1988-09-15	1989-09-14	イノシトールトリホスフェートを含有する組織の損傷に対する医薬
JP1237431A JP3058334B2 (ja)	1988-09-15	1989-09-14	イノシトールトリホスフェートを含有するリポ蛋白質の異常レベルに対する医薬
DE8989117028T DE68904507T2 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat bei der behandlung der beschaedigung von gewebe.
EP89117030A EP0359258B1 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltrisphosphat zur Herstellung eines Arzneimittels gegen Knochenerkrankungen
EP89117032A EP0359260B1 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen abnorme Konzentrationen von Lipoproteinen
ES89117031T ES2043998T3 (es)	1988-09-15	1989-09-14	El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes.
AT8989117030T ATE104855T1 (de)	1988-09-15	1989-09-14	Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
JP1237428A JPH02191218A (ja)	1988-09-15	1989-09-14	イノシトールトリホスフェートを含有する糖尿病の合併症に対する医薬
GB8920806A GB2223169B (en)	1988-09-15	1989-09-14	Inositol trisphosphate for the treatment of bone disorders
DE68922165T DE68922165T2 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen Diabetes.
ES89117029T ES2073419T3 (es)	1988-09-15	1989-09-14	Uso de inositatrifosfato en la preparacion de un medicamento contra la diabetes.
GB8920807A GB2223403B (en)	1988-09-15	1989-09-14	Inositoltrisphosphate for the treatment of disorders related to transplantation
GB8920805A GB2223168B (en)	1988-09-15	1989-09-14	Pharmaceutical composition comprising inositoltrisphosphate for the treatment of complications of diabetes
ES89117028T ES2045319T3 (es)	1988-09-15	1989-09-14	El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
JP1237430A JP2859319B2 (ja)	1988-09-15	1989-09-14	イノシトールトリホスフェートを含有する移植に関する障害に対する医薬
EP89117031A EP0359259B1 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen Störungen bei Transplantationen
DE68914922T DE68914922T2 (de)	1988-09-15	1989-09-14	Verwendung von Inositoltrisphosphat zur Herstellung eines Arzneimittels gegen Knochenerkrakungen.
AT89117028T ATE84719T1 (de)	1988-09-15	1989-09-14	Verwendung von inositoltriphosphat bei der behandlung der beschaedigung von gewebe.
JP1237429A JP2859318B2 (ja)	1988-09-15	1989-09-14	イノシトールトリホスフェートを含有する骨疾患に対する医薬
SE9003395A SE9003395L (sv)	1988-09-15	1990-10-24	Anvaendning av inositoltrifosfat foer framstaellning av laekemedel
GR920400982T GR3005448T3 (de)	1988-09-15	1992-08-20
GR920402459T GR3006825T3 (de)	1988-09-15	1993-01-21
GR930400188T GR3007686T3 (de)	1988-09-15	1993-04-22
GR940403975T GR3015764T3 (en)	1988-09-15	1995-04-13	Use of inositol triphosphate in the preparation of a medicament against diabetes.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8803248A SE464059C (sv)	1988-09-15	1988-09-15	Användning av inositoltrifosfat för framställning av läkemedel

Publications (4)

Publication Number	Publication Date
SE8803248D0 SE8803248D0 (sv)	1988-09-15
SE8803248L SE8803248L (sv)	1990-03-16
SE464059B SE464059B (sv)	1991-03-04
SE464059C true SE464059C (sv)	1997-06-02

Family

ID=20373330

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SE8803248A SE464059C (sv)	1988-09-15	1988-09-15	Användning av inositoltrifosfat för framställning av läkemedel
SE9003395A SE9003395L (sv)	1988-09-15	1990-10-24	Anvaendning av inositoltrifosfat foer framstaellning av laekemedel

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SE9003395A SE9003395L (sv)	1988-09-15	1990-10-24	Anvaendning av inositoltrifosfat foer framstaellning av laekemedel

Country Status (8)

Country	Link
EP (5)	EP0359256B1 (de)
JP (5)	JP3058334B2 (de)
AT (5)	ATE84719T1 (de)
DE (5)	DE68902526T2 (de)
ES (5)	ES2073419T3 (de)
GB (5)	GB2223404B (de)
GR (4)	GR3005448T3 (de)
SE (2)	SE464059C (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5330979A (en) *	1984-10-23	1994-07-19	Perstorp Ab	Method of treating renal disorders with inositoltriphosphate
US5428066A (en) *	1989-03-08	1995-06-27	Larner; Joseph	Method of reducing elevated blood sugar in humans
US5750348A (en) *	1989-03-08	1998-05-12	The University Of Virginia Patents Foundation	Method for detecting insulin resistance
AU647735B2 (en) *	1989-03-08	1994-03-31	University Of Virginia Alumni Patents Foundation, The	Dietary supplement for insulin-resistant diabetics
US5427956A (en) *	1989-03-08	1995-06-27	The University Of Virginia Patent Foundation	Quantitative analysis for diabetic condition predictor
SE9002278L (sv) *	1990-06-28	1991-12-29	Perstorp Ab	Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
SE467340B (sv) *	1990-07-04	1992-07-06	Perstorp Ab	Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist
JP2750239B2 (ja) *	1991-08-14	1998-05-13	三共株式会社	アデノホスチンａまたはｂならびにその製法
SE503122C2 (sv) *	1993-11-22	1996-03-25	Perstorp Ab	Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
SE9600194D0 (sv) *	1996-01-19	1996-01-19	Perstorp Ab	A new chemical compound
US5880098A (en) *	1996-04-12	1999-03-09	Pharmacia & Upjohn Aktiebolag	Therapeutic treatment
SE9601396D0 (sv) *	1996-04-12	1996-04-12	Dieter Haeussinger	New therapeutic treatment 2
SE9602463D0 (sv) *	1996-06-24	1996-06-24	Perstorp Ab	The use of growth factor modulating compounds
US5998485A (en) *	1997-06-16	1999-12-07	Cedars-Sinai Medical Center	Method for modulating immune response with inositol
US5906979A (en) *	1998-01-27	1999-05-25	Insmed Pharmaceuticals, Inc.	Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
US6486127B1 (en)	2001-05-23	2002-11-26	Insmed, Incorporated	Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
KR100653557B1 (ko) *	2001-10-06	2006-12-05	아미코젠주식회사	카이로 이노시톨 또는 피니톨의 백내장 예방치료제로서의용도와 그 조성물
KR102666724B1 (ko) *	2017-10-26	2024-05-20	오츠카 세이야쿠 가부시키가이샤	이노시톨인산 함유 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE465951B (sv) *	1984-10-23	1991-11-25	Perstorp Ab	Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US4735902A (en) *	1984-10-23	1988-04-05	Matti Siren	Stabilized composition containing inositoltriphosphate
SE465305B (sv) *	1986-04-16	1991-08-26	Perstorp Ab	Anvaendning av inositolfosfat foer framstaellning av ett laekemedel

1988
- 1988-09-15 SE SE8803248A patent/SE464059C/sv not_active IP Right Cessation
1989
- 1989-09-14 JP JP1237431A patent/JP3058334B2/ja not_active Expired - Lifetime
- 1989-09-14 EP EP89117028A patent/EP0359256B1/de not_active Expired - Lifetime
- 1989-09-14 ES ES89117029T patent/ES2073419T3/es not_active Expired - Lifetime
- 1989-09-14 ES ES89117032T patent/ES2054965T3/es not_active Expired - Lifetime
- 1989-09-14 GB GB8920811A patent/GB2223404B/en not_active Expired - Lifetime
- 1989-09-14 EP EP89117031A patent/EP0359259B1/de not_active Expired - Lifetime
- 1989-09-14 AT AT89117028T patent/ATE84719T1/de not_active IP Right Cessation
- 1989-09-14 DE DE8989117031T patent/DE68902526T2/de not_active Expired - Fee Related
- 1989-09-14 AT AT89117029T patent/ATE120958T1/de not_active IP Right Cessation
- 1989-09-14 JP JP1237429A patent/JP2859318B2/ja not_active Expired - Fee Related
- 1989-09-14 EP EP89117032A patent/EP0359260B1/de not_active Expired - Lifetime
- 1989-09-14 ES ES89117028T patent/ES2045319T3/es not_active Expired - Lifetime
- 1989-09-14 GB GB8920805A patent/GB2223168B/en not_active Expired - Lifetime
- 1989-09-14 DE DE89117032T patent/DE68906106T2/de not_active Expired - Fee Related
- 1989-09-14 JP JP1237428A patent/JPH02191218A/ja active Pending
- 1989-09-14 DE DE68922165T patent/DE68922165T2/de not_active Expired - Fee Related
- 1989-09-14 EP EP89117030A patent/EP0359258B1/de not_active Expired - Lifetime
- 1989-09-14 EP EP89117029A patent/EP0359257B1/de not_active Expired - Lifetime
- 1989-09-14 AT AT89117032T patent/ATE88347T1/de not_active IP Right Cessation
- 1989-09-14 AT AT8989117030T patent/ATE104855T1/de not_active IP Right Cessation
- 1989-09-14 ES ES89117031T patent/ES2043998T3/es not_active Expired - Lifetime
- 1989-09-14 AT AT89117031T patent/ATE79542T1/de not_active IP Right Cessation
- 1989-09-14 ES ES89117030T patent/ES2055772T3/es not_active Expired - Lifetime
- 1989-09-14 GB GB8920804A patent/GB2223167B/en not_active Expired - Lifetime
- 1989-09-14 DE DE68914922T patent/DE68914922T2/de not_active Expired - Fee Related
- 1989-09-14 GB GB8920807A patent/GB2223403B/en not_active Expired - Lifetime
- 1989-09-14 GB GB8920806A patent/GB2223169B/en not_active Expired - Lifetime
- 1989-09-14 JP JP1237430A patent/JP2859319B2/ja not_active Expired - Fee Related
- 1989-09-14 DE DE8989117028T patent/DE68904507T2/de not_active Expired - Fee Related
- 1989-09-14 JP JP1237427A patent/JP2547257B2/ja not_active Expired - Fee Related
1990
- 1990-10-24 SE SE9003395A patent/SE9003395L/ not_active Application Discontinuation
1992
- 1992-08-20 GR GR920400982T patent/GR3005448T3/el unknown
1993
- 1993-01-21 GR GR920402459T patent/GR3006825T3/el unknown
- 1993-04-22 GR GR930400188T patent/GR3007686T3/el unknown
1995
- 1995-04-13 GR GR940403975T patent/GR3015764T3/el unknown

Also Published As

Publication number	Publication date
GB2223168B (en)	1992-08-12
DE68922165D1 (de)	1995-05-18
SE464059B (sv)	1991-03-04
JPH02191218A (ja)	1990-07-27
ATE88347T1 (de)	1993-05-15
DE68904507D1 (de)	1993-03-04
DE68906106T2 (de)	1993-10-21
ATE120958T1 (de)	1995-04-15
EP0359256B1 (de)	1993-01-20
JP2859319B2 (ja)	1999-02-17
GB2223404A (en)	1990-04-11
ES2045319T3 (es)	1994-01-16
GB8920807D0 (en)	1989-11-01
GB2223167A (en)	1990-04-04
SE8803248L (sv)	1990-03-16
EP0359258A2 (de)	1990-03-21
ATE79542T1 (de)	1992-09-15
EP0359256A3 (en)	1990-10-10
ATE84719T1 (de)	1993-02-15
GB8920811D0 (en)	1989-11-01
ES2054965T3 (es)	1994-08-16
GR3015764T3 (en)	1995-07-31
EP0359258A3 (en)	1990-10-03
SE9003395L (sv)	1992-04-25
ES2043998T3 (es)	1994-01-01
DE68922165T2 (de)	1995-09-14
JP2547257B2 (ja)	1996-10-23
GR3007686T3 (de)	1993-08-31
EP0359257A3 (en)	1990-10-03
GB8920806D0 (en)	1989-11-01
EP0359257B1 (de)	1995-04-12
GR3005448T3 (de)	1993-05-24
JPH02191220A (ja)	1990-07-27
EP0359260B1 (de)	1993-04-21
ES2055772T3 (es)	1994-09-01
DE68904507T2 (de)	1993-06-09
EP0359256A2 (de)	1990-03-21
EP0359259A2 (de)	1990-03-21
SE9003395D0 (sv)	1990-10-24
GB8920804D0 (en)	1989-11-01
DE68914922T2 (de)	1994-09-01
DE68914922D1 (de)	1994-06-01
GR3006825T3 (de)	1993-06-30
DE68902526T2 (de)	1993-03-11
EP0359258B1 (de)	1994-04-27
EP0359259B1 (de)	1992-08-19
JP3058334B2 (ja)	2000-07-04
JPH02191221A (ja)	1990-07-27
GB2223168A (en)	1990-04-04
GB2223403A (en)	1990-04-11
GB2223404B (en)	1992-04-08
ATE104855T1 (de)	1994-05-15
GB2223403B (en)	1992-02-26
EP0359260A3 (en)	1990-10-03
ES2073419T3 (es)	1995-08-16
EP0359259A3 (en)	1990-10-03
JP2859318B2 (ja)	1999-02-17
DE68902526D1 (de)	1992-09-24
DE68906106D1 (de)	1993-05-27
EP0359257A2 (de)	1990-03-21
SE8803248D0 (sv)	1988-09-15
GB2223169A (en)	1990-04-04
JPH02191219A (ja)	1990-07-27
EP0359260A2 (de)	1990-03-21
GB8920805D0 (en)	1989-11-01
JPH02191217A (ja)	1990-07-27
GB2223167B (en)	1992-02-26
GB2223169B (en)	1992-04-08

Legal Events

Date

Code

Title

Description

2000-05-15

NUG

Patent has lapsed

Ref document number: 8803248-7

Format of ref document f/p: F

Publication	Publication Date	Title
SE464059C (sv)	1997-06-02	Användning av inositoltrifosfat för framställning av läkemedel
US5003098A (en)	1991-03-26	Method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug
JP2528115B2 (ja)	1996-08-28	イノシト−ルトリホスフエ−トを含有する医薬組成物
US5015634A (en)	1991-05-14	Method of treating tissue damage with inositol triphosphate
EP0505452B1 (de)	1996-06-19	Verwendung von inositolphosphat zur herstellung eines arzneimittels
EP0941088B1 (de)	2003-03-05	Verwendung von konjugiertes linolensäure zur steigerung der aktivität von natural killer-lymphozyten
US6255291B1 (en)	2001-07-03	Composition and method for treating cancer and immunological disorders resulting in chronic conditions
US5057507A (en)	1991-10-15	Method of alleviating bone damage with inositoltriphosphate
WO1991009604A1 (en)	1991-07-11	A pharmaceutical composition comprising a phosphosugar
US2893914A (en)	1959-07-07	Thiadicarbocyanine anthelmintic compositions and methods of using them
SE501284C2 (sv)	1995-01-09	Användning av inositoltrifosfat för framställning av ett läkemedel
RU2554767C2 (ru)	2015-06-27	Препарат для стимуляции обменных процессов и ростовой активности телят
US3224939A (en)	1965-12-21	Method for treating helminthic infections
SE470511B (sv)	1994-06-27	Användning av inositolreisfosfat för beredning av läkemedel
DE10135395A1 (de)	2003-02-13	Organo-Phosphorverbindungen zur Aktivierung von gamma/delta-T-Zellen
HK1120371B (en)	2010-08-27	Novel use of a polyamine-depleted food composition for human or veterinary use, for preparing a therapeutic food product
HK1120371A1 (zh)	2009-04-03	用於制作人类或畜类药用食物产品，不含聚胺食物组分的新用途
WO1990004400A1 (en)	1990-05-03	PROCESS FOR INCREASING PHOSPHATIDYLCHOLINE $i(IN VIVO)